The American Journal of Drug and Alcohol Abuse
June 5, 2021
David J. Cox, Albert Garcia‐romeu, Matthew W. Johnson
29 citations
Background: Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patterns of tobacco, opioid, and alcohol consumption. But, the specific characteristics of psychedelic experiences that lead to changes in drug consumption are unknown.Objective: Determine whether quantitative descriptions of psychedelic experiences...
BJPsych Open
June 1, 2021
Jessica Lochtenberg, Ari P. Kirshenbaum, Matthew Johnson
Aims: A variety of pharmacotherapies have been used to assist the psychotherapy process as “adjunctive therapies.” These drugs are used in an acute, targeted fashion, such that they are explicitly delivered in the context of psychotherapy for anxiety, mood and substance-dependence disorders (SUDs). Our narrative review highlights the potential of medically-assisted psychotherapy by outlining...
BJPsych Open
June 1, 2021
Amber Elyse Corrigan, Ella Burchill, Lucy Pelton et al.
1 citation
Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a significant burden of treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic, found as the active compound in 'magic mushrooms', has been proposed as a novel therapeutic avenue for TRD. We aimed to evaluate the future feasibility and...
Journal of Psychopharmacology
May 29, 2021
Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann et al.
87 citations
Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed...
Scientific Reports
May 25, 2021
Patrick Vizeli, Isabelle Straumann, Friederike Holze et al.
54 citations
Lysergic acid diethylamide (LSD) is a classic psychedelic substance that is used recreationally and investigated in psychiatric research. There are no pharmacogenetic studies on LSD. In vitro metabolic studies indicate that several cytochrome P450 (CYP) isoforms (e.g., CYP2D6, CYP1A2, and CYP2C9) are involved in LSD metabolism, but in vivo data are scarce. The present study examined the...
Science
May 21, 2021
Kelly Servick
MDMA tested along with talk therapy, but the ideal pairing has yet to be studied.
AJN, American Journal of Nursing
May 19, 2021
Betsy Todd
Editor's note: From its first issue in 1900 through to the present day, AJN has unparalleled archives detailing nurses' work and lives over more than a century. These articles not only chronicle nursing's growth as a profession within the context of the events of the day, but also reveal prevailing societal attitudes about women, health care, and human rights. Today's nursing school curricula...
AJN, American Journal of Nursing
May 19, 2021
Diane Szulecki
Figure: This month's cover features a colorized magnetic resonance imaging scan of a human brain—a nod to Penn and colleagues' article “Psychedelic-Assisted Therapy,” which presents an overview of a growing field that nurses are positioned to be part of. Photo by Daisy Daisy / Shutterstock.This month's cover features a colorized magnetic resonance imaging scan of a human brain—a nod to Penn and...
May 19, 2021
Evan Lewis-Healey, Ruben Laukkonen, Michiel van Elk
4 citations
preprint
Objective: Recent clinical trials have demonstrated that psilocybin may have strong antidepressant effects, and may be effective in the treatment of depressive disorders when embedded in a psychotherapeutic protocol (psilocybin-assisted psychotherapy; PAP). However, despite promising results, the mechanism(s) that may be responsible for the antidepressant effects of PAP remain contested. Within...
Cureus
May 17, 2021
Sarah Tedesco, Ganeya Gajaram, Shahzad Chida et al.
31 citations
Background: 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as "Molly" or "Ecstasy", is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological profiles remains a controversial subject. Studies have shown the...